Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.

Is Back on Investors’ Radar Pfizer (PFE) is attracting fresh attention after a period of mixed share performance, with the ...

Both could reward patient investors down the line.

Pfizer will now employ Novavax’s adjuvant, Matrix-M, into its vaccines across two disease areas.

Novavax has agreed to a deal to let Pfizer use Matrix-M adjuvant in its products for an upfront payment of $30 million and up to another $500 million in milestone payments.

The healthcare giant has had trouble winning over investors in the past year despite an incredibly low valuation.

By Michael Erman and Christy Santhosh Jan 20 (Reuters) - Novavax said on Tuesday it signed a licensing agreement allowing ...

Novavax (NASDAQ:NVAX) got a lift early Tuesday after the vaccine maker landed a licensing deal with Pfizer that puts its ...

The agreement allows Pfizer to utilize Novavax’s Matrix-M adjuvant in up to two disease areas with its products. Under the terms of the deal, Novavax will receive an upfront payment of $30 million and ...

Under the terms of the agreement, Pfizer is expected to pay an upfront total of $30 million in early 2026 to Novavax, while ...

Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine ...

Novavax shares are trading higher Tuesday after the company announced it entered into a license agreement with Pfizer for ...